Page 4 - Pharma Sector

Shilpa Medicare hits 5% upper circuit; here's what sparked the rally today

Around 1:30 PM, Shilpa Medicare shares continued to trade 2.04 per cent higher at ₹833.95 per share. In comparison, BSE Sensex was trading flat at 82,176.17 levels.

Cohance Lifesciences shares slide 8% on block deals; Likely seller here

Cohance Lifesciences shares fell the most since August 14, after about 8.9 per cent stake changed hands on the NSE

India's bulk drug makers start preparing for Ozempic patent expiry

From local giants Dr Reddy's Laboratories Ltd. to suppliers like Macleods Pharmaceuticals Ltd., Indian firms are preparing to make bulk drugs

Novartis' Vymada patent revoked, generics set to slash prices by 70%

Novartis lost its Vymada patent in India, enabling generic drugmakers to launch versions that could slash prices by up to 70 per cent and improve access for cardiac patients

NPPA asks pharma firms to pass on GST rate cut benefits from Sept 22

The National Pharmaceutical Pricing Authority has asked pharmaceutical companies and medical device makers to pass on the benefit of reduced GST rates to consumers with effect from September 22. "The benefit of reduction in GST rates shall be passed on to consumers/patients effective from September 22, 2025. All the manufacturers /marketing companies selling drugs/formulations shall revise theP of drugs/formulations (including medical devices) accordingly, with effect from September 22," the authority said in an order. The manufacturer and marketing companies shall issue a revised price list or supplementary price list to the dealers, retailers, state drug controllers and the government, reflecting the revised GST rates and revisedP, the National Pharmaceutical Pricing Authority (NPPA) stated. Manufacturer and marketing companies shall take immediate measures to sensitise dealers, retailers, and consumers about the reduction in GST rates through all possible channels of communicatio

Pharma, medtech bodies seek transition time and simpler refunds

Industry bodies asked the govt for a three-month transition period, use of old packaging, and a simpler GST refund mechanism to avoid supply chain disruptions in healthcare

Biocon inaugurates first manufacturing facility in New Jersey's Cranbury

Biocon Ltd on Thursday said it has inaugurated its first manufacturing facility in the US, located in Cranbury, New Jersey. The company's wholly-owned subsidiary, Biocon Generics Inc. (BGI), operates the plant. Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc in 2023 and has since invested over USD 30 million to establish a plant with an annual production capacity of 2 billion tablets. A few products have already been commercialised from the site, with several more in the pipeline, the Bengaluru-based firm said in a statement. This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint, it added. "Biocon's first USFDA-approved formulations facility in New Jersey marks a new chapter in our journey of global expansion," Kiran Mazumdar-Shaw, Chairperson of Biocon Group, said. The facility reflects the company's long-term commitment to deeper engagement with healthcare provide

Cotec Healthcare files draft papers with Sebi to raise funds through IPO

Pharmaceutical company Cotec Healthcare Ltd has filed preliminary papers with capital markets regulator Sebi to raise funds through an initial public offering (IPO). The proposed IPO comprises a fresh issue of equity shares aggregating up to Rs 295 crore, along with an offer for sale (OFS) component of 60 lakh shares, according to the draft red herring prospectus (DRHP) filed on Thursday. Under the OFS, promoters Harsh Tiwari and Vandana Tiwari will offload 30 lakh equity shares each. The company proposes to utilise proceeds from the fresh issue worth Rs 226.25 crore for setting up anew project aimed at enhancing existing manufacturing capacities and facilitating the manufacture of new products. Besides, a portion of the proceeds will also used for general corporate purposes. Cotec Healthcare is a leading player in the contract development and manufacturing organization (CDMO) industry in India. Its CDMO offerings include formulation, loan licensing and commercial manufacturing of

Sun Pharma's Halol plant gets OAI classification from US FDA inspection

US FDA has classified Sun Pharma's Halol facility in Gujarat as OAI, keeping it under import alert, signalling possible enforcement action unless corrective steps are taken

Pharma market grows 8.7% in August; cardiac and anti-diabetic segments lead

The Indian Pharma Market grew 8.7% in August 2025, with the cardiac, anti-diabetic, and anti-neoplastic segments driving growth. Sun Pharma maintained its leadership position

Glenmark Pharma up 3% on DCGI nod to start phase 3 trial of Envafolimab

Around 11:20 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 3.05 per cent at ₹2,051.40 per share. In comparison, BSE Sensex was trading 0.25 per cent lower at 80,518.51 levels.

Pharma stock up 37% in 6 mths; Nuvama initiates with 'Buy', eyes 29% gains

According to Nuvama analysts Shrikant Akolkar, Aashita Jain and Gaurav Lakhotia, the company is positioned for robust growth over the medium-term, driven by capacity expansion and product additions.

Health ministry looks to reduce drug development, approval timelines

The Union Health Ministry has proposed amendments to NDCT Rules 2019 to reduce test licence timelines from 90 to 45 days and ease approvals for BA/BE studies

Trump plans hefty tax on imported drugs, risking higher prices, shortages

President Donald Trump has plastered tariffs on products from almost every country on earth. He's targeted specific imports, including autos, steel and aluminium. But he isn't done yet. Trump has promised to impose hefty import taxes on pharmaceuticals, a category of products he's largely spared in his trade war. For decades, in fact, imported medicine has mostly been allowed to enter the United States duty-free. That's starting to change. US and European leaders recently detailed a trade deal that includes a 15 per cent tariff rate on some European goods brought into the United States, including pharmaceuticals. Trump is threatening duties of 200 per cent more on drugs made elsewhere. Shock and awe' is how Maytee Pereira of the tax and consulting firm PwC describes Trump's plans for drugmakers. This is an industry that's going from zero (tariffs) to the potential of 200 per cent.' Trump has promised Americans he'll lower their drug costs. But imposing stiff pharmaceutical tariffs

Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment

US pharma tariffs unlikely to hit Indian drugmakers materially: Ind-Ra

Ind-Ra said US tariffs may cause only short-term pricing impact for Indian pharma as firms remain fortified by diversification, strong balance sheets, and global market positioning

Turbocharging India: Assuming global economic leadership

Higher tariffs could render many Indian products uncompetitive in US markets and bring unfavourable repercussions to the domestic economy

Automobiles to pharma & healthcare: India Inc earnings stay in slow lane

Corporate profits remained weak in Q1FY26, amid single-digit growth in revenues for the ninth consecutive quarter

Shilpa Medicare share jumps 4% on 1:1 bonus issue; check record date here

Shilpa Medicare shares rose after the company announced a 1:1 bonus issue, with the Board approving the proposal in its meeting on August 13, 2025.

Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity

Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets diabetes and obesity, competing with Wegovy